Journal of the American Pharmacists Association : JAPhA
-
J Am Pharm Assoc (2003) · May 2002
Drotrecogin alfa (activated) approved for treatment of severe sepsis.
Drotrecogin alfa (activated) is a recombinant form of human activated protein C that has been shown to reduce mortality in severely septic patients with a high risk of death. Given the complexity of the inclusion and exclusion criteria, the stability and unique duration of infusion, and the cost of treatment, therapy with this agent should be carefully considered to ensure its appropriate use.
-
J Am Pharm Assoc (2003) · Mar 2002
Biography Historical ArticleGreat moments in pharmacy: development of the Robert Thom series depicting pharmacy's history.
-
J Am Pharm Assoc (2003) · Jan 2002
Patient satisfaction with pharmaceutical care: update of a validated instrument.
To develop a questionnaire for measuring patient satisfaction with pharmaceutical care and to establish its factorial composition. ⋯ The instrument provides information on patients' satisfaction with two dimensions of pharmacy services. The instrument may be useful to practicing pharmacists, but it should be used cautiously until it is tested among patrons of pharmacies known to provide different levels of care.
-
J Am Pharm Assoc (2003) · Jan 2002
ReviewMeeting the therapeutic challenge of the patient with osteoarthritis.
To discuss the diagnosis of osteoarthritis and the efficacy of available pharmacologic and nonpharmacologic treatment options. ⋯ If used properly, the ACR guidelines for the treatment of osteoarthritis are important tools in the care of the patient with this disease.
-
J Am Pharm Assoc (2003) · Nov 2001
Pharmaceutical care in chain pharmacies: beliefs and attitudes of pharmacists and patients.
To discuss with pharmacists and patients with reactive airways disease their beliefs about pharmaceutical care and the pharmacist's role in health care, obstacles to providing pharmaceutical care in community pharmacies, and strategies to overcome these obstacles. ⋯ Focus groups provided valuable information for designing pragmatic pharmaceutical care. The obstacles and possible solutions identified through the discussions represent fertile ground for designing innovative pharmaceutical care programs.